The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis
Abstract
Clinical data suggest concomitant therapy with bisphosphonates and parathyroid hormone (PTH) may blunt the anabolic effect of PTH; rodent models suggest that infrequently administered bisphosphonates may interact differently. To evaluate the effects of combination therapy with an intravenous infusion of zoledronic acid 5 mg and daily subcutaneous recombinant human (rh)PTH(1–34) (teriparatide) 20 µg versus either agent alone on bone mineral density (BMD) and bone turnover markers, we conducted a 1-year multicenter, multinational, randomized, partial double-blinded, controlled trial. 412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138). The primary endpoint was percentage increase in lumbar spine BMD (assessed by dual-energy X-ray absorptiometry [DXA]) at 52 weeks versus baseline. Secondary endpoints included change in BMD at the spine at earlier time points and at the total hip, trochanter, and femoral neck at all time points. At week 52, lumbar spine BMD had increased 7.5%, 7.0%, and 4.4% in the combination, teriparatide, and zoledronic acid groups, respectively (p < .001 for combination and teriparatide versus zoledronic acid). In the combination group, spine BMD increased more rapidly than with either agent alone (p < .001 versus both teriparatide and zoledronic acid at 13 and 26 weeks). Combination therapy increased total-hip BMD more than teriparatide alone at all times (all p < .01) and more than zoledronic acid at 13 weeks (p < .05), with final 52-week increments of 2.3%, 1.1%, and 2.2% in the combination, teriparatide, and zoledronic acid groups, respectively. With combination therapy, bone formation (assessed by serum N-terminal propeptide of type I collagen [PINP]) increased from 0 to 4 weeks, declined minimally from 4 to 8 weeks, and then rose throughout the trial, with levels above baseline from 6 to 12 months. Bone resorption (assessed by serum β-C-telopeptide of type I collagen [β-CTX]) was markedly reduced with combination therapy from 0 to 8 weeks (a reduction of similar magnitude to that seen with zoledronic acid alone), followed by a gradual increase after week 8, with levels remaining above baseline for the latter half of the year. Levels for both markers were significantly lower with combination therapy versus teriparatide alone (p < .002). Limitations of the study included its short duration, lack of endpoints beyond DXA-based BMD (e.g., quantitative computed tomography and finite-element modeling for bone strength), lack of teriparatide placebo, and insufficient power for fracture outcomes. We conclude that while teriparatide increases spine BMD more than zoledronic acid and zoledronic acid increases hip BMD more than teriparatide, combination therapy provides the largest, most rapid increments when both spine and hip sites are considered. © 2011 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationBlack, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
Self-citationThe Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035725 · Cited by 829
Lindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D., & Cosman, F. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02342-8 · Cited by 749
Self-citationThe Use of Biochemical Markers of Bone Turnover in Osteoporosis
Delmas, P. D., Eastell, R., Garnero, P., Seibel, M. J., & Stepan, J. (2000) · Osteoporosis International · doi:10.1007/s001980070002 · Cited by 722
Dempster, D. W., Cosman, F., Kurland, E. S., Zhou, H., Nieves, J., Woelfert, L., Shane, E., Plavetić, K., Müller, R., Bilezikian, J., et al. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1846 · Cited by 653
Self-citationJiang, Y., Zhao, J. J., Mitlak, B. H., Wang, O., Genant, H. K., & Eriksen, E. F. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.1932 · Cited by 616
Self-citationDobnig, H. (1995) · Endocrinology · doi:10.1210/en.136.8.3632 · Cited by 615
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
Ettinger, B., Martin, S. J., Crans, G., & Pavo, I. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040117 · Cited by 487
Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass
McClung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., & Eriksen, E. F. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1762 · Cited by 444
Self-citationAntifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
Wasnich, R. D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.231 · Cited by 417
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Roschger, P., Rinnerthaler, S., Yates, J., Rodan, G. A., Fratzl, P., & Klaushofer, K. (2001) · Bone · doi:10.1016/s8756-3282(01)00485-9 · Cited by 384
Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Self-citationCosman, F., Nieves, J., Woelfert, L., Formica, C., Gordon, S., Shen, V., & Lindsay, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.5.925 · Cited by 311
Self-citationLindsay, R., Cosman, F., Zhou, H., Bostrom, M. P., Shen, V. W., Cruz, J. D., Nieves, J. W., & Dempster, D. W. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051109 · Cited by 277
Self-citationKeaveny, T. M., Donley, D. W., Hoffmann, P. F., Mitlak, B. H., Glass, E. V., & San Martin, J. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061011 · Cited by 258
Boonen, S., Marin, F., Obermayer-Pietsch, B., Simões, M. E., Barker, C., Glass, E. V., Hadji, P., Lyritis, G., Oertel, H., Nickelsen, T., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0711 · Cited by 252
Self-citationDaily and Cyclic Parathyroid Hormone in Women Receiving Alendronate
Cosman, F., Nieves, J., Zion, M., Woelfert, L., Luckey, M., & Lindsay, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050157 · Cited by 250
Self-citationLindsay, R., Zhou, H., Cosman, F., Nieves, J., Dempster, D. W., & Hodsman, A. B. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070104 · Cited by 233
Self-citationMa, Y. L., Zeng, Q., Donley, D. W., Ste-Marie, L.-G., Gallagher, J. C., Dalsky, G. P., Marcus, R., & Eriksen, E. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060314 · Cited by 229
Self-citationMiller, P. D., Delmas, P. D., Lindsay, R., Watts, N. B., Luckey, M., Adachi, J., Saag, K., Greenspan, S. L., Seeman, E., Boonen, S., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0353 · Cited by 222
Self-citationCosman, F., Wermers, R. A., Recknor, C., Mauck, K. F., Xie, L., Glass, E. V., & Krege, J. H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2719 · Cited by 175
Self-citationGlover, S. J., Gall, M., Schoenborn-Kellenberger, O., Wagener, M., Garnero, P., Boonen, S., Cauley, J. A., Black, D. M., Delmas, P. D., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080703 · Cited by 167
Self-citationUUSIRASI, K., SEMANICK, L., ZANCHETTA, J., BOGADO, C., ERIKSEN, E., SATO, M., & BECK, T. (2005) · Bone · doi:10.1016/j.bone.2005.03.003 · Cited by 159
Self-citationSato, M., Westmore, M. S., Ma, Y. L., Schmidt, A., Zeng, Q. Q., Glass, E. V., Vahle, J. L., Brommage, R., Jerome, C. P., & Turner, C. H. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040112 · Cited by 153
Statistical Methods for Comparison to Placebo in Active-Control Trials
Hasselblad, V., & Kong, D. F. (2001) · Drug Information Journal · doi:10.1177/009286150103500212 · Cited by 139
Delmas, P. D., Li, Z., & Cooper, C. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301228 · Cited by 118
Borggrefe, J., Graeff, C., Nickélsen, T., Marín, F., & Glüer, C. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090820 · Cited by 115
Kuiper, J. W., van Kuijk, C., Grashuis, J. L., EDERVEEN, A. G. H., & Schütte, H. E. (1996) · Osteoporosis International · doi:10.1007/bf01626534 · Cited by 101
PTH and interactions with bisphosphonates.
Ja, G., Kneissel, M., Js, T., & Mosekilde, L. (2000) · PubMed · Cited by 67
Burr, D. B. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0023-9 · Cited by 43
Parathyroid hormone treatment for osteoporosis
Cosman, F. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32831a46d6 · Cited by 41
Self-citationCosman, F. (2009) · Endocrine Practice · doi:10.4158/ep08306.orr1 · Cited by 32
Self-citationPTH-analogs: Comparable or different?
Verhaar, H. J. J., & Lems, W. F. (2009) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2008.11.004 · Cited by 24
[Influence of bone marrow fat on the determination of bone mineral content by QCT].
Ikeda, T., & Sakurai, K. (1994) · PubMed · Cited by 7
Cited by
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Self-citationEastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 827
Drug therapy for osteoporosis in older adults
Reid, I. R., & Billington, E. O. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02646-5 · Cited by 698
Leder, B. Z., Tsai, J. N., Uihlein, A. V., Wallace, P. M., Lee, H., Neer, R. M., & Burnett-Bowie, S.-A. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61120-5 · Cited by 603
Metadata
- Authors
- Cosman, F., Eriksen, E. F., Recknor, C., Miller, P. D., Guañabens, N., Kasperk, C., Papanastasiou, P., Readie, A., Rao, H., Gasser, J. A., Bucci-Rechtweg, C., & Boonen, S.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-02
- Volume
- 26
- Issue
- 3
- Pages
- 503-511
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2041578222
- Cited by
- 359
- References
- 38
- FWCI
- 19.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.